Evidence map›Paper›PMID 40765099›Full record

ArticleCurrent drug discovery technologies2026

Debasmita Bhattacharya, Jai Gupta, Avi Gupta, Moupriya Nag, Dibyajit Lahiri, Debanjan Mitra

Abstract read
PubMed Publisher
In one paragraph

Article in Current drug discovery technologies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Debasmita BhattacharyaDepartment of Basic Science and Humanities, Institute of Engineering and Management, University of Engineering and Management, Kolkata, India.
Jai GuptaDepartment of Biotechnology, Institute of Engineering and Management, University of Engineering and Management, Kolkata, India.
Avi GuptaDepartment of Biotechnology, Institute of Engineering and Management, University of Engineering and Management, Kolkata, India.
Moupriya NagDepartment of Biotechnology, Institute of Engineering and Management, University of Engineering and Management, Kolkata, India.
Dibyajit LahiriDepartment of Biotechnology, Institute of Engineering and Management, University of Engineering and Management, Kolkata, India.
Debanjan MitraDepartment of Microbiology, Raiganj University, Raiganj, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAntibiotic resistance is a growing concern in the current world. Regarding this,

methodsIn this study, an overall bioinformatics analysis was conducted of the bioactive compound, along with some FDA-approved drugs, to identify potential novel treatments for diseases associated with

resultsA higher number of intra-protein interactions increases the stability of DISCUSSION: The target protein's structural and sequential analysis demonstrated how the correct number of amino acids boosts the protein's stability. The ability of bioactive chemicals to function as medications is indicated by their drug-likeness characteristics. According to toxicity evaluation, they do not have any serious effects when they come into contact with people through the environment. Liquiritin and Clarithromycin were the two top compounds that appeared as the best inhibitors.

conclusionBioactive compounds that can be used as drugs. This work will also be beneficial for the development of synthetic drugs.

Indexed as

Anti-Bacterial AgentsBiofilmsHelicobacter pyloriBacterial ProteinsComputer SimulationHelicobacter InfectionsHumansMolecular Docking SimulationAnti-Bacterial AgentsBacterial Proteinsacid-response system proteinADMETBiofilmH. pylorimolecular dockingnatural compounds

Identifiers

PMID40765099

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.